Drug intelligence / Profile preview

RJ014

Development stage: Preclinical
Lead developer: Risen
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

RJ014 is a preclinical-stage proteolysis-targeting chimera (PROTAC) being developed by Risen Shanghai Medical Technology (Risen Pharma) for the treatment of cancer. As a PROTAC, it is designed to recruit an E3 ubiquitin ligase to a specific target protein, leading to the protein's ubiquitination and subsequent degradation by the proteasome. While the specific molecular target for RJ014 remains undisclosed by the developer, it is part of Risen Pharma's pipeline of targeted protein degraders aimed at oncological indications.

Beyond the preview

Go deeper on RJ014.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RJ014.

Explore the full profile